Pictet Alternative Advisors

Tracked participation in 1 Atlas company, with 0 explicitly attributed leads.

1portfolio companies

1round participations

0lead positions

Sep 2023latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:Biomedicines—Sep 2023 → Sep 20231 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Sep 14, 2023GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:BiomedicinesSeries C$273M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗